Cocrystal Pharma, Inc. (COCP) 股票分析

公司概述

Cocrystal Pharma, Inc. operates as a biotechnology firm dedicated to the discovery and development of antiviral therapeutic treatments designed to address serious and chronic viral diseases within the United States market. The company leverages structure-based technologies to create antiviral drugs specifically targeting pathogens such as the influenza virus and coronaviruses, positioning it within the specialized healthcare sector. In terms of scale, the firm currently maintains a market capitalization of $19.71 million and employs approximately 10 individuals to execute its research and development mandates. The combination of a relatively small market cap and negligible annual revenue figures indicates that the company is in an early-stage development phase typical for biotechnology entities, where significant resources are allocated to clinical trials and drug formulation rather than commercial sales generation. This operational scale reflects the high-risk, high-reward nature of the biotech industry, where capital is heavily invested in bringing novel therapeutics to market before achieving substantial revenue streams.

财务健康

The financial statements reveal a revenue (TTM) figure that is not applicable, while the company reported a net income (TTM) of $-8,831,000 and an EBITDA of $-8,947,000. The absence of reported revenue paired with substantial net losses highlights a cost structure dominated by research and development expenses rather than operating costs associated with product sales. The company generated free cash flow of $-4,946,875, which signifies a continuous burn rate that consumes cash reserves and limits immediate financial flexibility for unexpected opportunities or strategic acquisitions. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet achieved profitability or generated gross sales to cover its operational expenditures. On the balance sheet, the firm holds $7.03 million in cash against $1.50 million in debt, resulting in a debt-to-equity ratio of 23.77, which suggests a leveraged position despite the lack of debt coverage by current cash balances. However, the current ratio stands at 3.68, indicating a strong short-term liquidity position where current assets significantly exceed current liabilities. Return on equity is calculated at -111.4% and return on assets at -48.7%, metrics that reveal management is currently operating with negative returns on both shareholder equity and total assets due to the lack of commercial earnings.

估值评估

The valuation metrics present a forward P/E of -1.47 while the trailing P/E (TTM) is not applicable, implying that the market prices the stock based on anticipated future earnings rather than historical performance. The price-to-book ratio is 3.12, suggesting that the market assigns a premium valuation to the company's intangible assets and potential intellectual property compared to its tangible book value. Alternative valuation metrics such as the price-to-sales ratio (not applicable) and EV/EBITDA of -1.59 further indicate that traditional valuation models relying on profitability are not currently effective for this biotechnology asset. Regarding trading range, the 52-week high is $2.67 and the 52-week low is $0.86; the current price sits at a level that reflects market volatility without reaching the upper threshold of the recent trading range. The beta value is 1.18, which indicates that the stock's price volatility is higher than that of the broader market, responding more aggressively to market-wide movements and sector-specific news.

Growth & Income

The revenue growth (YoY) and earnings growth (YoY) rates are both listed as not applicable, which precludes a direct comparison of earnings growth velocity against revenue expansion in the traditional sense. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a dividend yield of not applicable and a payout ratio of 0.0%. Consequently, the firm reinvests its limited free cash flow and remaining cash reserves directly back into its research programs and drug development pipeline rather than providing income to investors. The overall growth and income profile is characterized by a reliance on future commercialization success rather than current profitability or dividend generation, typical for early-stage biotechnology companies with a focus on long-term therapeutic breakthroughs.